Pamrevlumab

Last updated
Pamrevlumab
Monoclonal antibody
Type ?
Source Human
Target CTGF
Clinical data
Other namesFG-3019
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6492H10018N1718O2086S48
Molar mass 147050.38 g·mol−1

Pamrevlumab (INN; [1] development code FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. It binds to the connective tissue growth factor (CTGF) protein. [2]

This drug was developed by FibroGen. [3]

References

  1. ↑ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
  2. ↑ Sgalla G, Franciosa C, Simonetti J, Richeldi L (August 2020). "Pamrevlumab for the treatment of idiopathic pulmonary fibrosis". Expert Opinion on Investigational Drugs. 29 (8): 771–777. doi:10.1080/13543784.2020.1773790. PMID   32447983. S2CID   218873298.
  3. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Pamrevlumab, American Medical Association.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.